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    1) The early administration of methotrexate (MTX) was effective for suppression of 
 homograft response in mice lethally gamma-irradiated and transplanted with homologous 
 bone marrow (HBM), but survival rate thus obtained was still less than that when iso-
 logous bone marrow (IBM) was transplanted.. 
    2) The effect of MTX for suppression of homograft response in the mice lethally ir-
 radiated and transplanted with homologous spleen cells (HSC) was not satisfactory. 
    3) MTX for suppression of homograft response in the mice sublethally irradiated 
 and treated with HBM or HSC was highly effective. 
    4) The possible mechansism of MTX for suppression of homograft response was 
 discussed. 
                          INTRODUCTION 
   As previously described", pre-irradiation of the donor could not satisfactorily 
prevent so-called homograft response or delayed death. Therefore, in order to 
inhibit the homograft response the use of immunologically immature fetal liver 
as a protective agent in place of adult HBM has been studied, but the result 
does not seem to be always good2'. Drug treatment as a method of modifying the 
homograft response has been tried. Uphopff3' reported that the use of folic acid 
antagonist, methotrexate (MTX), might spare mice that would normally succumb 
to a homograft response following lethal total body X-irradiation and HBM treat-
ment in 1958 and, within a few years after-wards, 6-mercaptopurine41, azathi-
opurines> and cyclophosphamidee) were in use for this purpose. Recently, Fer-
rebee et al..° also reported that the early administration of MTX prevented the 
delayed foreign marrow reaction. The purpose of this experiment reported here 
is to ascertain the effect of MTX in the mice gamma-irradiated lethally or sub-
lethally under high dose rate and treated with homologous bone marrow (HBM) 
or homologous spleen cells (HSC). 
                    MATERIALS AND METHODS 
   Dd/s and Na2 strain mice were used as recipients and donors, respectively. 
* ~lt 
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They were supplied from the Kyoto University Animal Center. A Co 60 gamma-
irradiation facility which belongs to the Institute for Chemical Research of Kyoto 
University was used in the present experiments. The conditions of irradiation 
were described previously'". Lethal irradiation in this study means approxi-
mately 900 r irradiation which is 100 % lethal to mice within 30 days. LD 100 
dose of gamma-rays to mice can be given in less than half a minute. MTX 
(1.5 mg per kg body weight) usually injected intraperitoneally 4 times every 
other day, beginning 1 day after total body irradiation and HBM or HSC trans-
plantation. This is the early administration of MTX, while the delayed admini-
stration of MTX means that injections of MTX begin at 8 days or 14 days after 
irradiation. Bone marrow suspension was obtained by the method described 
previously". Spleen cell suspension was obtained by the following way ; removed 
donors' sleens were washed in cold Tyrode's solution, excluded surrounding tissues 
and capsules, scissored in the solution, pippeted more than ten times and the 
coarse particles settled down by gravity within half a minute. The remaining 
supernatant fluid was practically a single cell suspension. The number of the 
nucleated cells of bone marrow and spleen cell suspension inoculated per mouse 
was 10X106 to 15X106. 
                           RESULTS 
   1) Survival rate 
   At 900 r, as summarized in Table 1, ten types of experiments were carried 
out. In the experiment 1, the early administration of MTX was used, i.e., MTX 
was given at 1, 3, 5 and 7 days to the irradiated and HBM transplanted mice. 
The survival rates were 78 % at 21 days and 73 % at 30 days. It should be 
noted that they were much better than those of 30 % at 21 days and 20 % at 30 
days in the HBM transplantation alone in experiment 5. On the other hand, 
        Table 1. Suvival rate of lethally (900r) gamma-irrated mice treated with 
         HBM (or HSC) and Methotrexate (MTX). 
              infused MTX given No. of °° Survival (at days)     Exp. cell type on days mice 
7 14 21 30 60 90 
     1 HBM1, 3, 5, 7 22 100 91 78 73 45 32 
     2 HBM8,10,12,14 33 100 82 64 52 21 18 
     3 HBM14,16,18,20 10 70 70 50 40 40 40 
       4 HBM 1; 3, 5, 7, 9,11,13,15 18 100 50 28 17 5 5 
    5 HBMNone10 60 50 30 20 10 10 
    6 HSC1,3,5,764 84 69 45 36 16 11 
   7 HSCNone20 85 65 35 10 5 5 
    8 ISC1,3,5,78 100 88 88 88 88 88 
    9 ISCNone8 100 100 100 88 88 88 
   10 NoneNone20 40 0 
   MTX was given 1.5 mg/kg/mouse 
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the 30 day survival rates of the mice treated with both  HBM and the delayed 
administration of MTX were 52 % and 40 % in experiments 2 and 3, respectively. 
The mice treated with both HSC and the early administration of MTX showed 
36 % survival at 30 days in experiment 6. This survival rate was a little bet-
ter than that of 10 % at 30 days in the HSC transplantation alone in experiment 
7. At 90 days, there was not so much difference in the survival rate between 
the HSC-MTX treated mice and the HBM or HSC alone treated mice, while in 
both the isologous spleen cells (ISC)-MTX treated mice and the ISC alone treated 
mice, the survival rates were 88 % at 90 days as seen in experiments 8 and 9. 
   At 700 r, as shown in Table 2, the survival rate of the only irradiated mice 
in experiment 7, was 92 % at 90 days. This was not so much different from 
that of the mice treated with ISC or IBM. When the irradiated mice were 
treated with HSC or HBM, they showed very reduced survival, i.e., 6 % or 
33 %, respectively, at 90 days as seen in experiments 2 and 4. But the survival 
rate of the mice which were treated with HBM (or HSC) and MTX was 80 
or 69 %, at 90 days in experiments 1 and 3, respectively. 
   At 800 r, the only irradiated mice showed 44 % survival at 90 days, while 
most of the HSC treated mice died by 21 days. 
       Table 2. Survival rate of sublethally gamma-irradiated mice treated with 
        HBM (or HSC) and Methotrexate (MTX). 
           Dose of infused use of No. of % Survival (at days)    Exp. irrad. cell type MTX mice -7 14 21 30 60 90 
   1 700rHBM Yes 10 100 100 100 80 80 80 
   2HBM None 20 100 50 40 40 33 33 
3 700rHSC Yes 26 100 100 85 81 73 69 
  4HSC None 34 91 82 68 24 6 6 
5 700rIBM None 10 100 100 100 90 90 90 
   6ISC None 20 100 100 100 95 95 95 
7 700rNone None 24 96 92 92 92 92 92 
   8None Yes 8 100 100 100 100 100 100 
   9HSC Yes 18 67 61 55 55 55 55 
   10 800r HSC None 18 89 39 17 11 11 11 
  11None None 16 94 81 50 44 44 44 
   MTX was given on days 1,3,5, and 7. 
   2) Body weight change 
   At 900 r, body weight changes in both the HSC treated mice and the HBM 
or HSC and MTX treated mice are shown in Fig. 1. The weight of the HBM-
MTX treated mice reached almost the preirradiation level approximately at 20 
days after total body irradiation, and then decreased again. The early admini-
stration of MTX could not completely prevent delayed body weight change. In 
the HSC-MTX treated mice, body weight began to decrease again at 20 days or 
so after irradiation and did not show any tendency of recovery, while in both 
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the ISC and the ISC-MTX treated mice, body weight changes were almost the 
same as each other, i.e., they initially decreased, but afterwards showed tendency 
of recovery and then reached the preirradiation level by 30 days and thereafter 
increased gradually. 
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   At 700 r, as shown in Fig. 2, body weight changes in both the HBM-MTX 
treated mice and the HSC-MTX treated ones were almost the same, i.e., they 
did not show any decreasing tendency. When the mice were treated with HBM 
or HSC alone, they showed initial decrease in body weight, but that of the 
former gradually increased and almost at 20 days reached the preirradiation 
level and that of the latter temporarily increased, followed by a tendency of 
     100 :S= ~: ~------ 
            90 
— — 700r+HBM 
            80 ---------700r4 .11. spleen 
----- 700r only 
70——— 700r+H.spleen+Metholrexate                              (or 700r+HBM ethotr t )
-- — preimmunized+ 700r+H.spleen 
           60 
        10 20 30 
                                          days after irrad.
                       Fig. 2. Body weight changes (700r).
                            (106)
      Hematopoietic Cell Transplantation in Mice Irradiated with Gamma Rays. (II) 
gradual decrease and never reached the preirradiation level by 30 days. When 
the recipients were preimmunized with donor tissue homogenate 7 days pre-
viously and transplanted with HSC after the irradiation, they did not show any 
decreasing tendency in body weight. 
   3) Hematological findings 
   At 900 r, as shown in Figs. 3, 4, 5 and 6, changes of erythrocyte count platelet 
count and hemoglobin content of the ISC-MTX treated mice were almost the 
same as those of the ISC alone treated mice, except that the former had a  2-3 
day delayed beginning of recovery of leucocyte and reticulocyte count which 
subsequently increased quickly. In the HBM or HSC and MTX treated mice 
nearly the same tendency of retarded recovery of reticulocyte and leucocyte 
count was also observed. In general, the HSC treated mice seemed more anemic, 
even with the early administration of MTX. 
   At 700 r, as shown in Figs. 7, 8, 9 and 10, the IBM or ISC treated mice showed 
more rapid recovery of erythrocyte, reticulocyte and leucocute count and hemo-
globin content than those of the untreated mice. In the HBM or HSC treated 
mice here were not marked changes of leucocyte and reticulocyte count as com-
pared with those of the ISC treated mice, but the erythrocyte count and hemo-
globin content were decreased at the delayed stage of post-irradiation days which 
were prevented by the early administration of MTX. 
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were observed following the administration of MTX. 
   4) Histological findings 
   At 900 r, there were no marked qualitative differences of histological findings 
of hematopoietic tissues between the HBM or HSC and MTX treated mice and 
the controls which were treated with HBM alone, i.e., early regeneration of bone 
marrow occurred at 5-10 days after irrdiation and treatment, the red plup of 
spleen began to recover at about 9-40 days, and the white plup of spleen and 
the lymph nodes of some mice showed a few germinal center at the same days 
In some mice the regeneration of thymic cortex became marked by 8,-40 days 
(Fig. 11) . But some other mice which survived beyond 21 days had hypoplastic 
or aplastic bone marrow (Fig. 12-45), aplasia of lymphoid tissues including 
thymus (Fig. 16), emaciation, hemorrhage, diarrhea and ruffled fur, i.e., se-
condary bone marrow aplasia with wasting syndrome. Most of the survivors 
beyond 40 days showed almost complete recovery of the bone marrow and all 
lymphoid tissues. 
   At 700 r, histological findings of bone marrow and spleen of the HBM or HSC 
and MTX treated mice were not so much different from those of the HBM or 
HSC alone treated mice ; almost complete wasting by 4 days after irradiation 
followed by spotty regeneration of the bone marrow and early phase of the 
recovery of the red pulp of the spleen beginning at 4-5 days in the HBM or 
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HSC treated mice, while the recovery of the HBM or HSC and MTX treated 
mice began at  6.'10 days. Even in the controls which were irradiated and 
untreated, the bone marrow and the red pulp of the spleen began to recover at 
6-410 days. As to thymic recovery, there was a tedency of some retardation in 
the HBM or HSC alone treated mice except for some animals showing marked 
regeneration at 8-10 days, the majority of which belonged to the HBM treated 
mice. On the contrary, the irradiated and untreated mice showed comlete re-
covery of the thymus at 8-10 days. The HBM or HSC and MTX treated mice 
showed various manifestations of thymic recovery which were almost complete 
at 10--'13 days in some mice and incomplete in others with aplasia of other 
lymphoid tissues during the period of 60 post-irradiation days. Thymic recovery 
of the mice survived for 90 days was almost complete. 
                         DISCUSSION
   The ability of the folic acid antagonist to suppress immune response was 
first shown by Malmgren et al.8' who found that repeated injections of MTX in-
hibited antibody production in the mice that had been injected with sheep red 
cells. Subsequent works have confirmed the effect of this agent on production of 
humoral antibody9-12'. It has also been shown to inhibit the induction of de-
layed hypersensitivity13-16) and homograft responsel7'19'. The effectiveness of 
MTX to suppress homograft response in bone marrow transplantation was shown 
by Uphoff in 19583', who reported that the use of MTX spared mice that would 
otherwise succumb to a homograft response following total body X-irradiation 
and HBM transplantation and that the secondary weight loss which might be 
caused by the homograft response was also suppressed by the administration of 
MTX every other day 9 times beginning at 14 days after the total body irradation. 
But other workers" reported that the survival rates of mice treated with HBM 
and delayed administrations of MTX were 90% at 10 days and 20% at 30 days, 
while early administrations of MTX prevented delayed death, i.e., the survival 
rate was 100% at 90 days. In the present study reported above the survival 
rates of the mice lethally irradiated and treated with HBM and MTX which was 
given at 1, 3, 5 and 7 days after irradiation were 73% at 30 days and 32% at 90 
days. It should be noted that they were much better than those of 30% at 21 
days and 20% at 30 days in the group treated with HBM alone. Body weight 
changes of the HBM-MTX treated mice reached almost preirradiation level ap-
proximately at 20 days after irradiation, and then gradually decreased again. 
The survival rate of them also decreased to 45% at 60 days. When the delayed 
administration of MTX beginning at 8 days or 14 days was used, the survival 
rates were 52% or 40% at 30 days, respectively. These results suggest that an 
immune response was suppressed by the early administration of MTX at least 
for about 30 days, though it occurred in some mice later. But more than half of 
the mice lethally irradiated and treated with both HSC and early administered 
MTX died by 30 days, and their body weight began to decrease again at about 
20 days after irradiation and did not show any tendency of recovery, though the 
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  survival rate was a little better than that of the group treated with HSC alone. 
  It is well known that spleen cells can protect lethally irradiated mice, but it is 
  also believed so far that there are more lymphoreticular cells in the spleen of 
  mice than in the bone marrow. And it is generally accepted that the lymphore-
  ticular cells as the cells closely associated with cellular antibody play a major 
  role in homograft  response20>, though some workers insist that homograft response 
  depends upon serum antibody2',22>. These facts suggest that the effect of MTX 
  must diminish when the number of the transplanted immunologically comptent 
  cells increases. Therefore, it may be thought that the effect of MTX for immune 
  suppression of the HSC transplanted mice is less than that of MTX for suppres-
  sion of the HBM transplanted mice. The survival rates and histological findings 
  in ISC transplantation with and without MTX were almost the same as each 
  other. Therefore, it goes without saying that this dose of MTX used has no 
  marked toxicity in lethally gamma-irradiated mice, while Uphoff3> suggested that 
  MTX might be more toxic in lethally irradiated mice than in normal mice. As 
  for the effect of the early administration of MTX on homograft response in the 
  lethally irradiated and HBM transplanted mice, Ferrebee et al.7> discussed that, 
  if the reaction of immunologically competent cells on the marrow infusion could be 
  restrained during a short interval, either these cells passed through their life-span 
  and died without injuring the host, or they and their progeny acquired tolerance to 
  their environment without first having injured it and themselves by reaction. In 
  the present study, as above described, the immunologically competent cells also 
  seem to react in the early stage of recovery after the irradiation and it is pro-
  bable that the more the number of them is, the stronger the immune response 
  occurs. The effect of MTX is attributable largely to its ability to bind folic acid 
  reductase, an enzyme responsible for the conversion of folic to tetrahydrofolic 
  acid. The latter is a coenzyme for many biochemical reactions, the most im-
  portant of which is probably thymidine synthesis24>. Werkheiser25> suggests that 
  the different susceptibility of various tissues to folic acid antagonists may be 
  partly explained by differences in their permeability to the antagonist and the 
  time during which they can resist folic acid reductase inhibition without sustain-
  ing irreversible damage. On entering the cell, the antagonist binds folic acid re-
  ductase and thus strongly inhibits thymidine synthesis and processes dependent 
  on it, such as cell divission. Synthesis of proteins, including folic acid reductase, 
  is only moderately affected and Werkheiser suggests that the cells recovers when 
  sufficient folic acid reductase has been produced to enable thymidine synthesis, 
  unless it has suffered irreversible damage in the meantime. Berenbaum et al.26> 
  stated that, during the early stage of the immune response, antigenically 
 stimulated cells might be irreversibly damaged by only a few hour exposure to 
  folic acid antagonists, i.e., antigenically stimulated cells may have the special 
 susceptibility to MTX. Therefore, it should be considered that the immunological-
  ly competent cells infused to the irradiated but antigenically rich environment 
 may also have the special susceptibility to MTX during the early stage of im-
  mune response. In the present study MTX was noted to be highly effective for 
  the suppression against the development of the homograft response during 30 
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        Fig. 11. Beginning marked recovery of thymic  cortex  ; 10 days after 
         900r irradiation and HBM-MTX treatment. Bone marrow showed 
          marked regeneration. Nucleated cell count of one femur was 1.2x106. 
       Fig. 12. Aplastic bone marrow ; 36 days after 900r irradiation and 
         HSC-MTX treatment. Hemorrhages were seen in the intestinal tract 
         and mesenteric lymph node. Body weight was 24.3g before irradia-
         tion and decreased to 18.3g at the day of autopsy. All lymphoid 
          tissues were wasted. Nucleated cell count of one femur was 1.0 X106. 
       Fig. 13. Aplastic bone marrow ; 27 days after 900r irradiation and 
         HBM treatment. Hemorrhages were seen in the intestinal tract and 
         mesenteric lymph node. Body weight was 22.0g before irradiation 
         and decreased to 17.5g at the day of autopsy. 
       Fig. 14. Hypoplastic bone marrow ; 31 days after irradiation and HBM-
         MTX treatment. Mesenteric lymph node showed a few germinal 
          center. Thymus was almost wasted. Nucleated cell count of one 
          femur was 2.2x106. 
        Fig. 15. Localized aplastic bone marrow ; 28 days after irradiation 
         and HSC-MTX treatment. All lymphoid tissues were almost wasted. 
         Body weight was 22.3g before irradiation and decreased to 11.9g at 
         the day of autopsy. 
       Fig. 16. Complete wasting of the thymus of the mouse described in 
          Fig. 12. 
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days after irradiation and HBM transplantation when the early  administration 
of MTX in the dose of demonstrating no toxicity to normal mice was used. But. 
the survival rate thus obtained was still less than that after the IBM transplan-
tation. In order to suppress only immune response without causing lethal side. 
effect of the use of a large amount of MTX, Berenbaum et al. showed that the 
delayed administration of folinic acid reduced the toxicity of MTX for those 
tissues (presumably intestinal epithelium and bone marrow)27, damage to which 
causes weight loss and death, but did not reduce the toxicity of MTX for cells. 
participating in the early stage of the immune response. Therefore, it is con-
sidered that the combination of early MTX and delayed folinic acid administra-
tion may be more effective to prevent homograft response or delayed death, be-
cause much MTX can be given to the mice without causing serious side effects. 
   Recently the killing effect of infused homologous28-30 or heterologous31' hema-
topoietic cells for sublethally irradiated host mice was reported. According to. 
Uphoff's report, the killing effect depended on the strain combinations used and. 
the effect in certain combinations was modified by : delayed marrow inoculation,, 
use of substrain C3HeB as the irradiated host, and preimmunization of the ir-
radiated host. In the present study the lethal effect of Na2 HBM or HSC against 
dd/s host was also found ; the 30-day survival rates without transplantation 
were 92 % at 700 r and 44 % at 800 r, while they were 24 % and 40 % at 700 r 
with HSC and HBM, respectively, and 11 % at 800 r with HSC inoculation after 
irradiation. But MTX, when used after irradiation and HBM or HSC inocula- 
tion, altered the lethal effect ; the 30-day survival rates were about 80 % at. 
700 r and 55 % at 800 r. These data also indicate the MTX suppresses homo-
graft response. But, at the sublethal dose, the HBM or HSC transplanted and 
MTX administered mice without early mortality are probably thought to show 
reversion to the host phenotype, because the recovery pattern of their lymphoid 
tissues, which used to show important changes in homograft response, was al-
most the same as that in the irradiated and untreated mice, though some mice 
of the former group showed a tendency of retarded recovery of lymphoid tissues. 
Furthermore, the peripheral blood pictures showed quicker recovery than that 
of the irradiated and untreated mice. Uphoff stated30j that an experiment in 
which mice survived for 90 or more days after sublethal irradiation and HBM 
treatment provided further evidence for marrow rejection without lethality, i.e., 
these mice rejected tumor grafts of a strain specific neoplasm that grew only in 
the strain of the marrow donor : long-term protection might be a tiding-over 
phenomenon. The results obtained in the present study also suggest that, as 
Uphoff's theoretical implications, there may be not a simple graft rejection, but 
a tiding-over effect of the inoculated homologous cells with subseqent regression 
of th infused cells and reversion to the host phenotype. In general, it is thought 
that the early mortality of the sublethally irradiated and HBM or HSC treated 
mice is due to stronger and quicker recovery of host's immune state31'. Fur-
thermore, Trentin showed32' that the early motality at sublethal dose of irradia-
tion was observed in the parent mice infused with F1 hybrid, not in the F1 
hybrid infused with parent marrow, i.e., this type of mortality resulted from 
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      Hematopoietic Cell Transplantation in Mice Irradiated with Gamma Rays. (II) 
recovery of the host's ability to reject temporarily grafted marrow and there 
was usually secondary bone marrow aplasia. Schwartz et  a1.28) also reported 
that some of the mice infused with parental spleen cells died of bone marrow 
aplasia : in other mice, however, the bone marrow was cellular and the im-
mediate cause of death could not be given. In the present study, at 700 r, se-
condary bone marrow aplasia or hypoplasia in some mice, especially in the HSC 
alone treated mice, was also observed, but the cause of much lower 30-day 
survival of the HSC alone treated mice than that of the HBM alone treated 
mice did not seem to be ascribed only to secondary bone marrow aplasia. In 
order to clarify this difference between inoculations of HSC and HBM, further 
experiments are needed. As for the secondary bone marrow aplasia at the 
lethal dose of irradiation, de Vries et al.33> noted that it was caused by host 
against graft reaction and chiefly occurred before 30 days after irradiation, and 
that so-called homologous disease or delayed foreign marrow reaction which 
took place after the 30 th post-irradiation day was of a complex nature ; im-
paired recovery of radiation-induced lesions, decreased resistance to bacterial 
infections due probably to generalized atrophy of the lymphoid tissues, and also 
an immunological reaction of the graft against host were postulated to be causal 
factors. In the present study secondary bone marrow aplasia with marked 
secondary weight loss, ruffled fur, diarrhea and hemorrhage was also found. 
These results incicate that even in the stage of secondary bone marrow aplasia, 
the cause of death should be considered to be of a complex nature. 
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